On 20 July 2023, Sosei Group Corporation, which oversees GJE client and leading fully integrated biopharmaceutical company Heptares Therapeutics Limited, completed its acquisition of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China).
A GJE team headed by Ian Jones, with associates Ash Earl and Charlie O’Neill, provided IP support in the acquisition of Idorsia by Sosei Group Corporation as part of the due diligence for Pivlaz® (clazosentan) and daridorexant – drugs used to treat cerebral vasospasm and insomnia respectively.
To see how GJE supports in-house IP teams, please click here or contact Ian, Ash or Charlie who would be delighted to hear from you.
Related resources
Teva fined €462.6m for misuse of EPO patent system – time to rethink your divisional patent strategy?
In a rare but highly important decision involving European patents, the European Commission has recently found the pharmaceutical...
Changes to Marketing Authorisations and SPCs in the UK
The UK Intellectual Property Office (UKIPO) provided guidance on 31 October in relation to significant updates to marketing...
G1/23 – Does the Enlarged Board’s preliminary opinion shine a light on the state of the art?
The European Patent Office's Enlarged Board of Appeal has just given its preliminary opinion in respect of referral...
Does T 116/18 Tip the Balance in Favour of Patentees in the Post-Published Evidence Debate at the EPO?
The Enlarged Board of Appeal in G 2/21 established new requirements for determining when post‑published evidence can be...
G 1/22 and G 2/22: EPO Publishes Decision on Priority Entitlement
The EPO have published the eagerly anticipated G1/22 and G2/22 decision of the Enlarged Board of Appeal, providing...
Patent Law & Practice at a Glance
We regularly review changes to patent law and practice at the UKIPO, EPO and in other jurisdictions so...